NanoViricides to Present Broad-Spectrum Antiviral Pipeline at Spartan Capital Investor Conference
NanoViricides will present its clinical-stage antiviral drug pipeline at the Spartan Capital Investor Conference, highlighting the potential significance of its platform technology for treating multiple viral diseases including RSV, COVID-19, influenza, and other respiratory infections.
NanoViricides Inc. (NYSE American: NNVC), a clinical-stage developer of broad-spectrum antiviral drugs, announced it will present at the Spartan Capital Investor Conference in New York City on November 3, 2025. The presentation comes as the company advances its novel nanoviricide platform technology designed to prevent viral escape, addressing a critical limitation in current antiviral treatments.
The company's lead drug candidate, NV-387, represents a significant advancement in antiviral therapy with planned development for respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. This broad-spectrum approach could potentially address multiple viral threats with a single therapeutic platform, reducing development timelines and costs compared to virus-specific treatments.
NanoViricides' technology platform is based on intellectual property licensed from TheraCour Pharma Inc., with the company holding exclusive, sub-licensable field licenses for several viral disease categories. The company's business model involves licensing technology from TheraCour for specific application verticals of specific viruses, as established at its foundation in 2005. Additional information about the company's technology and pipeline is available at https://www.nanoviricides.com.
Beyond NV-387, the company is advancing NV-HHV-1 for shingles treatment and developing drugs against numerous other viral diseases including oral and genital herpes, viral eye diseases, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus. The platform technology's versatility across multiple virus families demonstrates its potential to address both common and emerging viral threats.
The company holds worldwide exclusive perpetual licenses for several major viral diseases including HIV/AIDS, Hepatitis B and C, Rabies, Herpes Simplex Virus, Varicella-Zoster Virus, Influenza, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The company intends to obtain additional licenses for RSV, Poxviruses, and Enteroviruses pending successful initial research outcomes.
Current development efforts are focused on advancing NV-387 into Phase II human clinical trials, though the company notes it cannot project exact dates for filing Investigational New Drug applications due to dependence on external collaborators and consultants. As with all pharmaceutical development, the path remains lengthy and capital-intensive, with no assurance that current candidates will demonstrate sufficient effectiveness and safety for successful clinical development. The latest updates regarding the company's progress are available at https://ibn.fm/NNVC.
The presentation at the Spartan Capital Investor Conference provides investors with insight into the company's progress and the potential impact of its platform technology on global antiviral treatment options. The broad-spectrum nature of NanoViricides' approach could potentially address the challenge of viral mutation and resistance that often limits the effectiveness of conventional antiviral medications.